This can explain that conversion disorder may develop following a threatening situation, that there may be a group effect with many people simultaneously developing similar symptoms (as in mass psychogenic illness), and the gender difference in prevalence.The Lacanian model accepts conversion disorder as a common phenomenon inherent in specific psychical structures. The higher prevalence of it among women is based on somewhat different intrapsychic relations to the body from those of typical males, which allows the formation of conversion symptoms. See also
Body-centred countertransference
Hysterical contagion
Mass hysteria
Posttraumatic stress disorder (PTSD) and Complex posttraumatic stress disorder (C-PTSD)
Somatization disorder
Functional neurological symptom disorder

References


== External links ==
However, at high istradefylline concentration, it causes locomotion depression akin to caffeine (which is a broad-spectrum adenosine receptor antagonist), and might do so by displacing adenosine, and working as a NAM towards D2R (instead of A2AR). History
It was first approved in Japan in 2013.The effectiveness of Nourianz in treating "off" episodes in patients with Parkinsons disease who are already being treated with levodopa/carbidopa was shown in four 12-week placebo-controlled clinical studies that included a total of 1,143 participants. In all four studies, people treated with Nourianz experienced a statistically significant decrease from baseline in daily "off" time compared to patients receiving a placebo.It was approved for medical use in the United States in 2019. and approval was granted to Kyowa Kirin, Inc.

References
External links
"Istradefylline". Drug Information Portal. U.S. National Library of Medicine.